Lung cancer accounts for the main proportion of malignancy-related deaths and most
patients are diagnosed at an advanced stage. Immunotherapy and targeted therapy have …

Targeted therapies have revolutionized the treatment and improved the outcome for
oncogene-driven NSCLC and an increasing number of oncogenic driver therapies have …

Background Sotorasib is a specific, irreversible inhibitor of the GTPase protein, KRAS G12C.
We compared the efficacy and safety of sotorasib with a standard-of-care treatment in …

Transcription factors (TFs) are indispensable for the modulation of various signaling
pathways associated with normal cell homeostasis and disease conditions. Among cancer …

Lung cancer is the deadliest cancer worldwide. Tissue biopsy is currently employed for the
diagnosis and molecular stratification of lung cancer. Liquid biopsy is a minimally invasive …

SMARCA4, also known as transcription activator, is an ATP-dependent catalytic subunit of
SWI/SNF (SWItch/Sucrose NonFermentable) chromatin-remodeling complexes that …

Antibodies targeting the immune checkpoint molecules PD-1, PD-L1 and CTLA-4,
administered alone or in combination with chemotherapy, are the standard of care in most …

Acquired resistance to tyrosine kinase inhibitors (TKI), such as osimertinib used to treat
EGFR-mutant lung adenocarcinomas, limits long-term efficacy and is frequently caused by …

Non-small cell lung cancer (NSCLC) is the leading cause of cancer deaths worldwide. Only
a fraction of NSCLC harbor actionable driver mutations and there is an urgent need for …

Compared with traditional therapies, targeted therapy has merits in selectivity, efficacy, and
tolerability. Small molecule inhibitors are one of the primary targeted therapies for cancer …